• Research and Development

    Shaping the
    future of medicine
    Start »

04/04/14, Research and Development Bayer to Present New Data on Advancing Oncology Portfolio New Preclinical and Early Clinical Data Evaluating Innovative Compounds in Drug Development more


02/10/14, Research and Development Two-Year Results From Phase III Trial of VEGF Trap-Eye (aflibercept solution for injection) for the Treatment of Diabetic Macular Edema Show Sustained Improvement in Vision more


At a glance

 

Research expenses 2013 EUR 1,654 million
In percent of division sales 2013
14,8%
Employees in Research & Development 7,800
(as of Dec 31, 2013)
Main research sites Berlin and Wuppertal, Germany and Berkeley, USA
Research focus
  • Berlin:
    oncology, women's healthcare
  • Wuppertal:
    Cardiology, oncology
  • Berkeley:
    Applied research and life cycle management in hemophilia and multiple sclerosis

more

Image: Research and Development

Promising pipeline ensures mid- and long-term innovation

Bayer HealthCare Pharmaceuticals concentrates its R&D activities on innovative treatment alternatives for diseases with a high unmet medical need to improve patients’ quality of life and prolong lives. The focus is on therapeutic areas with a high medical need, where more innovations are needed despite considerable progress.

We hold a leading position in many therapeutic fields: for instance in the treatment of hemophilia and multiple sclerosis, in contrast media and oral contraception. We are also striving for such a leading position in oncology.
more

Image: Clinical trials

About Clinical Trials

Clinical trials are used to evaluate potential treatments that have had some effect against disease in the lab, or in animal experiments. The whole point of a clinical trial is to find out if a treatment is effective.

Until sufficient results are available from many different trials it is just that, potential. Effectiveness of a treatment should never be at the expense of safety; the benefit of a treatment should always outweigh the harm and is fundamental to the conduct of all clinical trials.
more

Page tools
.
Interactive tool
Grants for Targets
Annual Report 2013
Clinical Trials

open
close
http://www.bayerpharma.com/en/research-and-development/index.php

Copyright © Bayer Pharma AG